It is important that clinicians involved in the care of those with T2D and ASCVD consider or advise the use of GLP-1 RAs as well as other agents proven to lower cardiovascular risk (eg, SGLT-2 inhibitors, antihypertensive agents, lipid-lowering drugs, and antiplatelet agents where indicated) to reduce future atherothrombotic events. Here, SLC5A2 is linked to type 2 diabetes mellitus.